M. Cazzola (Rome, Italy), I. Tillie-Leblond (Lille Cedex, France)
Expression of lymphocyte IL-4-receptor alpha chain in patients with severe asthma as a marker of severity of disease
V. Mineev, L. Sorokina, M. Nyoma, K. Sysoev, V. Trofimov (Saint-Petersburg, Russian Federation)
|   |
Risk factors associated with frequent exacerbations (FE) in severe asthma: a multicentre study in Japan
A. Niimi, M. Jinnai, M. Fujimura, Y. Nishimura, K. Ishihara, H. Yasuba, M. Arita, I. Goma, C. Yoshimura, Y. Suzuki, Y. Taguchi, H. Matsumoto, S. Fujieda, M. Mishima, Y. Tohda (Kyoto, Osaka, Japan)
| |
Leptin as a specific marker of risk factors in severe bronchial asthma
V. Mineev, L. Sorokina, V. Berestovskaya, M. Nyoma, V. Trofimov (Saint-Petersburg, Russian Federation)
| |
Nasal mucosa biopsy in patients with severe bronchial asthma
I. Malkusova, O. Ruzickova, V. Hrabe, M. Terl, P. Panzner (Pilsen, Czech Republic)
| |
Concordant reductions in total IgE and exhaled nitric oxide during oral steroid withdrawal in severe asthma at high altitude
L. H. Rijssenbeek, K. B. Fieten, A. O. Bron, E. J. Weersink, E. H. Bel (Davos, Switzerland; Amsterdam, Netherlands)
| |
A new cause of difficult to treat asthma
M. E. Heuvers, H. J. Kan, H. C. Hoogsteden, P. T. W. van Hal (Rotterdam, Netherlands)
| |
Italian real-life experience of omalizumab
M. Cazzola, L. Macchia, P. Paggiaro, Italian Omalizumab Group (Rome, Bari, Pisa, Origgio/VA, Italy)
| |
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
M. Molimard, R. Niven, R. Buhl, V. Le Gros, A. Thielen, J. Thirlwell, Z. Panahloo (Bordeaux, Rueil-Malmaison, France; Manchester, West Sussex, United Kingdom; Mainz, Nuremberg, Germany)
| |
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
P. Velling, D. Skowasch, S. Pabst, E. Jansen, C. Grohé (Berlin, Bonn, Germany)
| |
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
S. Zielen, A. Lieb, J. De Monchy, S. De la Motte, F. Wagner, R. Fuhr, C. Munzu, S. Koehne-Voss, G. J. Riviere, J. S. Jaffe (Frankfurt, Munich, Berlin, Germany; Groningen, Netherlands; West Sussex, United Kingdom; Basel, Switzerland; East Hanover, United States Of America)
| |
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
P. Magyar, C. Peckitt, R. Maykut, G. Peachey (Budapest, Hungary; West Sussex, United Kingdom; East Hanover, United States Of America)
| |
Improved symptom relief with omalizumab in the treatment of allergic rhinitis
B. Omarjee, B. Tanguy (Saint Denis, Reunion)
| |
Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE)
C. Kroegel, K. M. Stoiber, C. Kropf, S. Rüdiger, C. Heider, M. Foerster, A. Thielen, C. Schumann (Jena, Nürnberg, Ulm, Germany)
| |
Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation
G. J. Rivière, S. Abbi, S. Koehne-Voss, K. Kim, J. S. Jaffe (Basel, Switzerland; East Hanover, Cypress, United States Of America)
| |
Omalizumab: therapeutic approach to asthma and comorbidities
J. Gomes, A. Antunes, R. Duarte, J. Ferreira, J. Moreira Silva, A. Carvalho (Vila Nova de Gaia, Portugal)
| |
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
V. Knowles, M. Nordstrom, M. Britton (Surrey, United Kingdom)
| |
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma
L. Somerville, J. Bardelas, A. Viegas, P. D‘Andrea, J. Thirlwell, M. Massanari, G. Peachey (Houston, High Point, East Hanover, United States Of America; West Sussex, United Kingdom)
| |
Interferon-α (IFN-α)-treatment of uncontrolled severe persistent asthma. Results from a 12-month open label study
C. Heider, M. Foerster, A. Moeser, J. Happe, R. Walther, B. Bartuschka, A. Reissig, C. Kroegel (Jena, Germany)
| |
Differential expression of mRNA encoding for pro-inflammatory and angiogenic proteins in aspirin-tolerant and -intolerant asthma, following oral provocative aspirin challenge
G. Devouassoux, V. Barbalat, R. Dubost, S. Zaouche, C. Dubreuil, A. Pachot, P. Froehlich, M. H. Castaldi, R. Barnoud, J. Bienvenu, J. F. Cordier, N. Freymond, S. Isaac, L. Laforest, B. Macgregor, B. Mougin, Y. Pacheco (pierre-bénite, Lyon, France)
| |